NYSE:ALife Sciences
FDA Ovarian Cancer Nod Puts Focus On Agilent Valuation And Momentum
Agilent Technologies (NYSE:A) received FDA approval for its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic for Merck's KEYTRUDA in first line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
The approval extends the test's clinical use to a new ovarian cancer population where treatment options are limited.
Agilent Technologies, trading at around $124.88, now has fresh regulatory momentum behind its precision oncology portfolio. The stock has faced pressure...